London -One of the most powerful weapons to deal with disturbing new weaponsThe variant in the United States and the world may be a vaccine not yet approved by the FDA.
Earlier this month, the World Health Organization (WHO)It can be used internationally and has been distributed around the world to help fight COVID-19. But AstraZeneca is waiting for the results of the clinical trial in the United States, and it is expected to be completed in the next few weeks before applying it to the FDA.
At the same time, due to the fact that its vaccines are relatively easy to update, scientists at the University of Oxford in the United Kingdom are taking a preemptive approach to modify their vaccines to prevent new coronavirus variants (including those first discovered in South Africa) from being caught.
“Plug and Play”
Chief designer Sarah Gilbert (Sarah Gilbert) told CBS News that her team has been working on improving the vaccine to deal with new variants of the coronavirus for several months and hopes to have a new version ready in the fall.
Gilbert said the ability to open a dime depends on the “plug and play” platform used by the original Oxford vaccine.
She said: “You can decide which antigen to use and which antigen to use according to the virus you want to make a vaccine, and then insert it to make a vaccine.”
She also emphasized that since Oxford University has its own bio-manufacturing facilities on campus, modifications can be made quickly.
She said: “We have established channels.” “We produced the first vaccine stocks in our manufacturing facility in Oxford. It is only a few minutes away from campus.”
Gilbert said that a modified vaccine-not only can use variants from South Africa, but can also replace many interesting variants-can be launched in the United States within a few months.
Scientists at the University of Oxford say that even before modification, their vaccine can effectively solve the out-of-control variant first discovered in the UK. Preliminary data in real life show that its hospitalization rate has dropped by 94%, even surpassing Pfizer’s vaccine.
Andrew Pollard, the head of Oxford Vaccine Group, told CBS News: “In an environment where new variants have emerged, we have seen the first widespread use of vaccines.” It has an impact. This is really surprising.”
Pollard said that part of the success was due to the 12-week interval between the two shots in the United Kingdom, rather than the current standard four-week plan in the United States.
“If you give this vaccine as the first dose to more and more people, and immediately end hospitalization and death, and if you take two doses at the same time, you will selfishly inject those two doses to half of the people , This will slow down the deployment volume and protect the people.” Pollard said.
With more thanIn the United States, and as new variants continue to emerge, the demand for taking more photos faster has never been higher.